



NDA 202236/S-008

**SUPPLEMENT APPROVAL
FULFILLMENT OF POSTMARKETING
REQUIREMENTS**

Meda Pharmaceuticals, Inc.
265 Davidson Avenue
Somerset, NJ 08873-4120

Attention: Cindy Yayac
Senior Manager, Regulatory Affairs

Dear Ms. Yayac:

Please refer to your Supplemental New Drug Application (sNDA) dated August 22, 2014, received August 22, 2014, submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Dymista (azelastine hydrochloride and fluticasone propionate) Nasal Spray 137 mcg/50 mcg.

We acknowledge receipt of your amendments dated October 23, December 19, 2014, and January 21, and February 6, 16, and 19, 2015.

This “Prior Approval” supplemental new drug application provides for the use of Dymista (azelastine hydrochloride and fluticasone propionate) for the treatment of symptoms of seasonal allergic rhinitis in children 6 through 11 years of age.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Instruction for Use), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

FULFILLMENT OF POSTMARKETING REQUIREMENTS

We have received your submission dated August 22, 2014, containing the final reports for the following postmarketing requirements listed in the May 1, 2012, approval letter.

- 1888-1 Conduct a trial to evaluate the long-term safety of Dymista in children 4 to 11 years of age with seasonal allergic rhinitis or perennial allergic rhinitis.
- 1888-2 Conduct a trial to evaluate the efficacy and safety of Dymista in children 4 to 11 years of age with seasonal allergic rhinitis.

We have reviewed your submission and conclude that the above requirements were fulfilled.

This completes all of your postmarketing requirements acknowledged in our May 1, 2012, approval letter.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration

Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sadaf Nabavian, Regulatory Project Manager, at (301) 796-2777.

Sincerely,

{See appended electronic signature page}

Sally Seymour, MD
Deputy Director for Safety
Division of Pulmonary, Allergy, and
Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling (PI, PPI, IFU)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SALLY M SEYMOUR
02/20/2015